Aberrant expression of myogenin in inclusion body myositis: Immunohistochemical studies of transcription factors regulating myogenesis in inflammatory myopathies
Clinical and Experimental Neuroimmunology · 2012
DOI: 10.1111/cen3.12000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Neuroimmunology, 2012. Verfasst von Akatsuki Kubota und 3 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objectives
We aimed to assess the immunohistochemistry of transcription factors that regulate myogenesis ( P ax7, M yo D 1, and myogenin) in inflammatory myopathies in relation to histopathological severity, and to determine whether there are some differences in immunohistochemical findings between idiopathic inflammatory myopathy ( IIM ) and inclusion body myositis ( IBM ).
Methods
We assessed 49 biopsied muscle specimens: 32 from IIM patients, 13 from IBM patients, and four from control subjects. Each specimen was classified into one of four grades of histopathological severity. The numbers of regenerative myofibers and nuclei positive for P ax7, M yo D 1, or myogenin were counted.
Results
P ax7, M yo D 1, and myogenin showed specific nuclear staining patterns. Moreover, myogenin‐positive plaque‐shaped signals were observed within degenerative myofibers in IBM patients, and double immunofluorescence staining showed aggregation of myogenin within A β42‐positive inclusion bodies. The number of nuclei positive for P ax7, M yo D 1, or myogenin correlated with histopathological severity. In the specimens with moderate to severe histopathological changes, specimens from IBM patients showed less regenerative myofibers ( IIM , mean ± SD , 45.0 ± 22.9 per 100 myofibers; IBM , 17.7 ± 7.8 per 100 myofibers; P = 0.0007) and less myogenin‐positive nuclei ( IIM , mean ± SD , 7.28 ± 3.70 per 100 myofibers; IBM , 4.70 ± 1.40 per 100 myofibers; P = 0.0352) than those from IIM patients.
Conclusion
Aberrant localization of myogenin within degenerative myofibers in IBM may be related to the reduced numbers of regenerative fibers and myogenin‐positive nuclei in IBM . Further study is necessary to determine whether the expression of myogenin might be impaired in IBM .
Zitieren
APA
Kubota, A., Shimizu, J., Iwata, A., & Tsuji, S. (2012). Aberrant expression of myogenin in inclusion body myositis: Immunohistochemical studies of transcription factors regulating myogenesis in inflammatory myopathies. Clinical and Experimental Neuroimmunology. https://doi.org/10.1111/cen3.12000
Vancouver
Kubota A, Shimizu J, Iwata A, Tsuji S. Aberrant expression of myogenin in inclusion body myositis: Immunohistochemical studies of transcription factors regulating myogenesis in inflammatory myopathies. Clinical and Experimental Neuroimmunology. 2012. doi:10.1111/cen3.12000
BibTeX
@article{Kubota2012,
author = {Kubota, Akatsuki and Shimizu, Jun and Iwata, Atsushi and Tsuji, Shoji},
title = {Aberrant expression of myogenin in inclusion body myositis: Immunohistochemical studies of transcription factors regulating myogenesis in inflammatory myopathies},
journal = {Clinical and Experimental Neuroimmunology},
year = {2012},
doi = {10.1111/cen3.12000}
}
EUVIMED